Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...9293949596979899100101102...858859»
  • ||||||||||  Journal:  Potential mechanisms and drug prediction of Rheumatoid Arthritis and primary Sj (Pubmed Central) -  Feb 19, 2024   
    In conclusion, we identified commom targets as potential biomarkers in RA and pSS from publicly available databases and predicted potential drugs based on the targets. A new understanding of the molecular mechanisms associated with RA and pSS is provided according to the miRNA-gene network.
  • ||||||||||  Tepezza (teprotumumab) / Roche, Amgen
    Journal:  Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease. (Pubmed Central) -  Feb 19, 2024   
    There are some baseline measures, such as CAS and right and left gaze horizontal prism deviation that can help better predict how a patient will respond to teprotumumab treatment. Our results can better inform physicians of how to counsel patients with TED when considering teprotumumab therapy.
  • ||||||||||  Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
    Review, Journal:  Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions. (Pubmed Central) -  Feb 19, 2024   
    We systematically summarize recent advances in the discovery and optimization processes of direct KRAS inhibitors (including KRAS, KRAS, KRAS and KRAS inhibitors), indirect KRAS inhibitors (SOS1 and SHP2 inhibitors), pan-KRAS inhibitors, as well as proteolysis-targetingchimeras degrades and molecular chaperone modulators from the perspective of medicinal chemistry. We also discuss the current challenges and opportunities of KRAS inhibition and hope to shed light on future KRAS drug discovery.
  • ||||||||||  ivabradine / Generic mfg.
    Journal:  Ivabradine for congenital ectopic tachycardia in newborn. (Pubmed Central) -  Feb 19, 2024   
    Congenital junctional ectopic tachycardia is rare, and it is mostly resistant to the conventional treatment.Ivabradine is a new anti-arrhythmic agent, used extensively to decrease sinus rate in the treatment of cardiac failure. Ivabradine may be an option for the resistant congenital ectopic tachycardia.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Sensitization of cancer cells to ferroptosis coincident with cell cycle arrest. (Pubmed Central) -  Feb 19, 2024   
    A candidate orally bioavailable GPX4 inhibitor increases lipid peroxidation and shrinks tumor volumes when combined with a CDK4/6 inhibitor. Thus, cell cycle arrest may make certain cancer cells more susceptible to ferroptosis in
  • ||||||||||  Ibrance (palbociclib) / Pfizer, giredestrant (GDC-9545) / Roche
    Journal, Metastases:  Phase Ia/b Study of Giredestrant  (Pubmed Central) -  Feb 19, 2024   
    P1
    Giredestrant was well tolerated and clinically active in patients who progressed on prior ET. Results warrant further evaluation of giredestrant in randomized trials in early- and late-stage ER+ breast cancer.
  • ||||||||||  Jakafi (ruxolitinib) / Incyte, Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Trial completion date, Trial primary completion date, Metastases:  Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov) -  Feb 19, 2024   
    P1,  N=40, Recruiting, 
    Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024 Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025
  • ||||||||||  Prolia (denosumab) / Amgen
    Giant Cell Tumor of Bone with H3F3A Mutation and Unusual Bone Formation; Features to Separate from Low-Grade Central Osteosarcoma (Exhibit Hall; Poster Board Number: 80) -  Feb 18, 2024 - Abstract #USCAP2024USCAP_1193;    
    GCT-UBF generally exhibits separate fragments of non-lacelike woven bone, mild to moderate cellularity, rare to absent osteoclast-type giant cells or mitoses, H3F3A mutation and flat copy number changes, with lack of significant atypia, necrosis, additional pathogenic gene alterations or MDM2 amplification, distinguishing these from LG-OSA. A small subset with atypical features and multiple copy number alterations raise concern for malignancy and require further study.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    To B or Not to B: Utility of PAX5 in Lineage Assignment of Acute Leukemia (Exhibit Hall; Poster Board Number: 310) -  Feb 18, 2024 - Abstract #USCAP2024USCAP_1150;    
    In urgent cases where CD19 is dim and other markers by flow such as CD79a, CD22 are not uniformly strong, adding PAX5 can "rescue" the leukemia lineage assignment. Recent genome-wide CRISPR screens demonstrate that PAX5 modulates blinatumomab response in B-ALL; possible future directions include studying ways of quantitatively measuring PAX5 expression in these tumors as a predictive marker.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Immuno-Analytics of Patients with Gastric Cancer: Impact of Systemic Polychemotherapy on Peripheral T-Cell Fitness and Immunologic Features of Gastric Cancer Tissue () -  Feb 16, 2024 - Abstract #ITOC2024ITOC_101;    
    A novel bispecific antibody directed against Mucin 17 was developed and is currently being tested in an early first in human clinical trial (AMG 199)...Results Polychemotherapy consisting of 5-FU, docetaxel and oxaliplatin led to an increase in CD8 + T cells and a shift towards memory T cells, whereas the proportion of Tregs was stable...Hence, our data encourage the concept of sequencing bispecifics in a short time interval after completion of polychemotherapy. Further immunomonitoring is crucial for validating and advancing this combination approach.
  • ||||||||||  Journal:  Multitarget Potential Drug Candidates for High-Grade Gliomas Identified by Multiple Reaction Monitoring Coupled with In Silico Drug Repurposing. (Pubmed Central) -  Feb 16, 2024   
    The top drug candidates such as Pazopanib, Icotinib, Entrectinib, Regorafenib, and Cabozantinib were explored for their drug-likeness properties using the SwissADME...HGG cell lines showed enhanced cytotoxicity and cell proliferation inhibition with Pazopanib and Temozolomide combinatorial treatment compared to Temozolomide alone...While the present study identified five multitarget-directed potential drug candidates, future clinical studies in larger cohorts are crucial to evaluate the efficacy of these molecular candidates. The research strategy and methodology used in the present study offer new avenues for innovation in drug discovery and development which may prove useful, particularly for cancers with low cure rates.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie
    P1/2 data, Clinical Trial,Phase II, Journal:  A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. (Pubmed Central) -  Feb 16, 2024   
    P1/2
    The research strategy and methodology used in the present study offer new avenues for innovation in drug discovery and development which may prove useful, particularly for cancers with low cure rates. Patients received the mini-hyper-CVD regimen (dose-attenuated hyperfractionated cyclophosphamide, vincristine, and dexamethasone alternating with methotrexate and cytarabine) in combination with venetoclax (200
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Enrollment change, Trial termination:  Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease (clinicaltrials.gov) -  Feb 16, 2024   
    P=N/A,  N=30, Terminated, 
    Patients received the mini-hyper-CVD regimen (dose-attenuated hyperfractionated cyclophosphamide, vincristine, and dexamethasone alternating with methotrexate and cytarabine) in combination with venetoclax (200 N=60 --> 30 | Unknown status --> Terminated; Research group transferred to another hospital
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly
    Trial primary completion date, Metastases:  LCCC1717: Palbociclib and Cetuximab in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=24, Active, not recruiting, 
    Trial primary completion date: Dec 2023 --> Jul 2024 Trial primary completion date: Jan 2026 --> May 2023
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial completion date, Trial initiation date, Trial primary completion date:  Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=30, Recruiting, 
    Trial primary completion date: Jan 2024 --> Jul 2024 Trial completion date: Aug 2029 --> Nov 2029 | Initiation date: Dec 2023 --> Apr 2024 | Trial primary completion date: Aug 2028 --> Nov 2028
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Trial completion date, Trial primary completion date:  Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=31, Recruiting, 
    Trial completion date: Dec 2025 --> Aug 2025 Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
  • ||||||||||  Truqap (capivasertib) / Otsuka, AstraZeneca
    Trial completion date, Trial primary completion date, Metastases:  Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (clinicaltrials.gov) -  Feb 15, 2024   
    P3,  N=895, Recruiting, 
    Trial completion date: Apr 2031 --> Sep 2031 | Trial primary completion date: Jul 2026 --> Dec 2026 Trial completion date: Nov 2028 --> Aug 2029 | Trial primary completion date: Aug 2026 --> Nov 2027
  • ||||||||||  carvedilol / Generic mfg., ivabradine / Generic mfg.
    Trial completion date, Trial primary completion date:  Ivabradine in Cirrhotic Cardiomyopathy (clinicaltrials.gov) -  Feb 15, 2024   
    P=N/A,  N=130, Recruiting, 
    Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion date:  Denosumab for Smoldering Multiple Myeloma (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=20, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024 Trial completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Balversa (erdafitinib) / J&J
    Trial completion date, Metastases:  Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=35, Active, not recruiting, 
    Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025 Trial completion date: Dec 2023 --> Sep 2024
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer
    Trial completion date, Trial primary completion date:  NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=65, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024